Class I: Intrabony defect
Class II: Supracrestal defect
Class III: Combined defect
This therapeutic modality is applied to non-contained defects. Non-contained defect configurations might be attributable to the lack of adjacent bony peaks, implant position, or the pattern of bone loss in a bucco-lingual perspective. In other words, class Ia, II, and IIb are candidates for resective therapy (Fig. 2).
Flap design relies primarily on bone defect depth assessed using bone sounding and the width of keratinized mucosa (KM). It must be kept in mind that the goal is to reduce pocket depth; nevertheless, maintenance of ≥2 mm of keratinized mucosa on the buccal aspect is desirable. In scenarios with a narrow band of keratinized mucosa at the buccal aspect, a conservative approach in the buccal aspect is recommended as well as limiting excision to the palatal/lingual aspect. If no KM is present whatsoever, simultaneous soft tissue conditioning using a free epithelialized graft is indicated (Monje et al. 2020; Monje et al. 2021). For that, a full-thickness flap should be raised in the crestal area to access the uneven alveolar bone architecture and a partial thickness on the buccal flange to leave the periosteum attached to the bone. Osteoplasty and/or ostectomy must be performed with a diamond bur at the crestal aspect. Implantoplasty is recommended given that the implant surface will be deliberately exposed to the oral cavity, and any macro-geometrical (threads) and micro-structural (topographic roughed characteristics) features may lead to re-contamination of the pathogenic microbiome. The flap should be apically repositioned using an external vertical mattress suture.
A full-thickness flap must be raised to achieve access. Subsequently, debridement can be performed with curettes or ultrasonic devices. Surface decontamination is key to success (Fig. 3). The therapeutic strategy relies vastly on implant position. If the implant is within the bony housing, reconstructive therapy is indicated after comprehensive surface detoxification (Monje et al. 2022). Given that these defects are contained or partially contained, a volume-stable bone grafting material or a barrier membrane may favor graft stability. On the other hand, if the implant is outside of the bony housing, implantoplasty is advised for the area where the reparative potential is incomplete (see the combined therapy). For the intrabony component within the bony housing, reconstructive therapy is indicated (Monje & Schwarz, 2021). Repositioning of the flap is recommended, given that mucosal recession will spontaneously occur in the aspect where implantoplasty was performed. That, together with bone reconstruction in the intrabony component, would mediate the resolution of inflammation by reducing pocket depth. If, at the re-assessment, there is no or limited band of keratinized mucosa, it might be advisable to augment it by means of a free epithelialized graft.
A full-thickness flap must be elevated to access the defect. In the case of abundant KM, partial excision of the epithelium is recommended. Otherwise, an intra-sulcular incision must be performed with the goal of isolating the soft tissue lesion and leaving it attached to the implant and bone defect. The lesion must be removed using curettes. Implantoplasty is recommended for the supracrestal component, while surface decontamination strategies are to be applied in the intrabony compartment. If the implant is slightly outside the bony housing, implantoplasty would also be indicated for this aspect. This is the so-called combined therapy described initially elsewhere (Schwarz et al. 2011). Due to the nature of the defect, stabilizing bone fillers with a barrier membrane is encouraged. The flap must be apically positioned to reduce pocket depth. As a result, the polished surface will be exposed to the oral cavity.Again, if there is no or limited band of keratinized mucosa at the re-assessment, it might be advisable to augment it by means of a free epithelialized graft.
Surgical therapeutic strategies are proposed according to defect configuration to achieve clinical resolution of disease using flattening bone architecture. Further, it is critical to address local factors related to soft tissue characteristics and prosthesis design that contribute to disease initiation and may lead to recurrence. Adherence to a periodic supportive maintenance program is decisive for long-term stability.
Read the original article here: https://blog.iti.org/clinical-insights/surgical-therapeutic-modalities-of-peri-implantitis/
Alberto Monje Correa
Alberto Monje Correa, DDS, MS, PhD He obtained the MS at the Department of Periodontology and Oral Medicine at the University of Michigan, as well as an ITI Scholarship in the Department of Oral Surgery and Implantology at the University of Bern, Switzerland. He obtained the American board in periodontology from the American Academy of Periodontology, as well as the title of Doctor of Dentistry from the University of Granada.He is the head of the division of periodontics at CICOM-Monje in Badajoz, Spain, a task he combines with teaching, working as an associate professor at the International University of Catalonia (UIC) and at the University of Michigan in the United States. He is the co-editor of the book “Unfolding peri-implantitis”
Aghazadeh A, Persson RG, Renvert S. Impact of bone defect morphology on the outcome of reconstructive treatment of peri-implantitis. Int J Implant Dent 2020; 6:33.
Blanco C, Linares A, Dopico J, et al. Peri-implantitis, systemic inflammation, and dyslipidemia: a cross-sectional biochemical study. J Periodontal Implant Sci 2021; 51:342-351.
Chaushu L, Tal H, Sculean A, Fernandez-Tome B, Chaushu G. Peri-implant disease affects systemic complete blood count values-an experimental in vivo study. Clin Oral Investig 2020; 24:4531-4539.
Faggion CM, Jr., Chambrone L, Listl S, Tu YK. Network meta-analysis for evaluating interventions in implant dentistry: the case of peri-implantitis treatment. Clin Implant Dent Relat Res 2013; 15:576-588.
Hentenaar DFM, De Waal YCM, Van Winkelhoff AJ, Meijer HJA, Raghoebar GM. Non-surgical peri-implantitis treatment using a pocket irrigator device; clinical, microbiological, radiographical and patient-centred outcomes-A pilot study. Int J Dent Hyg 2020; 18:403-412.
Monje A, Amerio E, Cha JK, et al. Strategies for implant surface decontamination in peri-implantitis therapy. Int J Oral Implantol (Berl) 2022; 15:213-248.
Monje A, Blasi G, Nart J, Urban IA, Nevins M, Wang HL. Soft Tissue Conditioning for the Surgical Therapy of Peri-implantitis: A Prospective 12-Month Study. Int J Periodontics Restorative Dent 2020; 40:899-906.
Monje A, Pons R, Amerio E, Wang HL, Nart J. Resolution of peri-implantitis by means of implantoplasty as adjunct to surgical therapy: A retrospective study. Journal of periodontology 2021.
Monje A, Schwarz F. Principles of Combined Surgical Therapy for the Management of Peri-Implantitis. Clin Adv Periodontics 2021.
Schwarz F, Sahm N, Iglhaut G, Becker J. Impact of the method of surface debridement and decontamination on the clinical outcome following combined surgical therapy of peri-implantitis: a randomized controlled clinical study. J Clin Periodontol 2011; 38:276-284.
Schwarz F, Sahm N, Schwarz K, Becker J. Impact of defect configuration on the clinical outcome following surgical regenerative therapy of peri-implantitis. J Clin Periodontol 2010; 37:449-455.
Advertisement